The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.

Patients younger than 50 years diagnosed with EOCRC were more likely to have a benign colon indication, bleeding, and family history of CRC.

An investigator presented results from a pre-specified primary efficacy analysis of the phase 2 EXTEND trial testing the progression-free survival (PFS) benefits of metastasis-directed therapy by ...

Effective coordination among multidisciplinary team and individualized management strategies has emerged as a cornerstone of optimal NET care.

Researchers sought to determine whether zanubrutinib would outperform acalabrutinib in an indirect treatment comparison in R/R CLL.